Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DME (ID: DEB3CV1)

• DME Name: UDP-glucuronosyltransferase 2B7 (UGT2B7) DME Info
• Gene Name: UGT2B7

Molecule-Related Drug & Molecule List

46 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[1]
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[2]
Ambrisentan	DMD1QXW	Pulmonary arterial hypertension	BB01.0	Approved	[3]
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[4]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[5]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[6]
Carprofen	DMHMP05	Pain	MG30-MG3Z	Approved	[7]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[8]
Cenobamate	DM8KLU9	Complex partial seizure	8A68.0	Approved	[9]
Codeine	DMJX6ZG	Allergic rhinitis	CA08.0	Approved	[10]
Dapagliflozin	DM28UJG	Non-insulin dependent diabetes	5A11	Approved	[11]
Dexibuprofen	DMFYBD0	Ankylosing spondylitis	FA92.0	Approved	[12]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[12]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[13]
Empagliflozin	DMRF9YK	Type-1 diabetes	5A10	Approved	[14]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[12]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[16]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[12]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[17]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[18]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[12]
Indomethacin	DMSC4A7	Bursitis		Approved	[19]
Ketorolac	DMI4EL5	Postoperative inflammation	1A00-CA43.1	Approved	[20]
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[21]
Lorazepam	DM84ZXF	Absence epilepsy		Approved	[22]
Losartan	DM72JXH	Diabetic kidney disease	GB61.Z	Approved	[12]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[23]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[24]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[25]
Mycophenolic acid	DMRBMAU	Crohn disease	DD70	Approved	[26]
Naproxen	DMZ5RGV	Bursitis		Approved	[12]
Oxazepam	DMXNZM4	Alcohol withdrawal delirium		Approved	[27]
PF-04971729	DM79VXT	Type-2 diabetes	5A11	Approved	[28]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[29]
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[30]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[23]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[31]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[32]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[33]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[34]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[35]
Acemetacin	DML6CN4	N. A.	N. A.	Phase 4	[36]
Dihydrocodeine	DMB0FWL	Allergic rhinitis	CA08.0	Phase 4	[37]
Zaltoprofen	DM9RJH7	N. A.	N. A.	Phase 4	[12]

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CS-600G	DM1PV4Y	N. A.	N. A.	Phase 3	[38]
Dabigatran etexilate	DMRDZ4X	Venous thromboembolism	BD72	Phase 3	[39]
LCQ908	DMFLJHQ	Familial chylomicronemia syndrome	5C80	Phase 3	[40]
Rivoglitazone	DMBY31K	Ocular inflammation	9C61.24	Phase 3	[41]
Bevirimat	DML2D8Q	Human immunodeficiency virus infection	1C62	Phase 2	[42]
Lersivirine	DMSEVBH	Human immunodeficiency virus infection	1C62	Phase 2	[43]
Vadimezan	DMK7CYX	Solid tumour/cancer	2A00-2F9Z	Phase 2	[44]
SALVINORIN A	DMJ3HQY	Cerebral vasospasm	BA85.Z	Phase 1	[45]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-dihydroaldosterone	DM6ZTOW	N. A.	N. A.	Investigative	[2]
Tetrahydroaldosterone	DM2QKOU	N. A.	N. A.	Investigative	[2]

References

• [1] Product characteristics of Triumeq.
• [2] Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68.
• [3] Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
• [4] In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
• [5] Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
• [6] Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
• [7] Enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT) 2B7. Chirality. 2015 Mar;27(3):189-93.
• [8] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [9] FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
• [10] Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4.
• [11] Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
• [12] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [13] Eurartesim - European Medicines Agency
• [14] Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
• [15] Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006 Dec;34(12):2097-101.
• [16] Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
• [17] The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
• [18] Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
• [19] Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
• [20] Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
• [21] Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
• [22] Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
• [23] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [24] Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53.
• [25] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [26] Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
• [27] Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65.
• [28] The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443.
• [29] Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
• [30] Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
• [31] Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
• [32] Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
• [33] Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
• [34] Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
• [35] Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
• [36] Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.
• [37] Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
• [38] Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics. 2018 Aug 2;10(3). pii: E112.
• [39] Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75.
• [40] Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
• [41] In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
• [42] Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
• [43] Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.
• [44] Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.
• [45] Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.